An article published in Nature Immunology reports that Neuropilin-1 (NRP1) acts as a memory checkpoint for T cells that limits long-term antitumor immunity. The study is the result of a collaboration between researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. 

"Our findings point to an important new biological anti-tumor mechanism that we can exploit to provide durable, long-term immune response against tumors," says Dario Vignali, co-author. Only a third of patients respond to existing immunotherapies, and relapse is common. 

The team focused on studying Neuropilin-1 and the role it plays in the immune response suppression to cancer. "We knew NRP1 was present on the surface of other T cells, but we wondered whether it somehow altered the function of the killer T cells," says Chang "Gracie" Liu, first author.  "We thought it might function like any other immune checkpoint molecule and that blocking it would prevent tumors from growing."

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The first approach involved the creation of genetically modified mice where NRP1 had been removed from the surface of killer T cells. Expecting a slower growth rate, they were surprised to find no difference at all in the tumor presence of the experimental model when compared to normal mice.  Liu adds, “instead of giving up, we asked a different question: does NRP1 change the capability of the immune system to remember the tumor?"

Their second approach gave dramatic results: they removed the tumors and mimicked how a tumor recurs naturally in patients by placing the cells in a different location. The genetically modified model was better protected against relapse and responded better to anti PD1 immunotherapy than normal mice.  

Later experiments revealed that neuropilin was responsible for how T cells establish immune memory. NRP1’s presence causes killer T cells to become tired and therefore less effective at fighting cancer cells, particularly long-term. Removing the protein resulted in an increased ability of the immune response to battling the tumor a second time. "This is a completely new area of understanding of how anti-tumor immunity is controlled and will present new therapeutic opportunities to promote and enhance a more durable, long-term anti-tumor response in cancer patients," says Vignali.